Principal Display Panel (30 mL Vial Carton)
Ultomiris Solution, Concentrate
Product Images NDC 25682-028
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ultomiris (NDC 25682-028). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alexion Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Ultomiris 02
This text appears to provide information about a medication called ULTOMIRIS® and its dosage, dilution, and administration instructions. The medication is available in a 30 mL single-dose vial that must be diluted with 0.9% Sodium Chloride Injection prior to use. The medication should be protected from light and should not be frozen or shaken. The medication guide enclosed in the package must be dispensed to each patient. There is also information about the manufacturer of the medication, Alexion Pharmaceuticals, Inc.*
Ultomiris 03
Ultomiris 04
Ultomiris (ravulizumab-cwvz) is an injection for intravenous infusion containing 100 mg ravulizumab-cwvz, along with other ingredients. It must be administered through a 0.2 or 0.22-micron filter and does not contain preservatives. The drug should be stored at a temperature between 2°C and 8°C, and away from light. Alesion Pharmaceuticals Inc. manufactures Ultomiris. The prescribing information is available in a medication guide that should be given to each patient. The available lot is 932-01.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
